Nirsevimab 100 mg syringe shortage has resulted in updated guidance from the Centers for Disease Control and Prevention (CDC) for how to prioritize nirsevimab administration. Per their guidance, 100 mg doses should be reserved for infants less than 6 months old and infants with underlying conditions that place them at highest risk for severe RSV disease.
Update: Nirsevimab 100 mg Syringe Shortage
Related Articles
Over-the-Counter Preferred Drug List for Ohio Medicaid Plans
The Partners For Kids’ Pharmacy Team has created a list containing covered pediatric over-the-counter medications for patients insured by an Ohio Medicaid plan.
Read More
Over-the-Counter Preferred Drug List for Ohio Medicaid Plans
The Partners For Kids’ Pharmacy Team has created a list containing covered pediatric over-the-counter medications for patients insured by an Ohio Medicaid plan.
Read More
Updated: Urinary Tract Infections Prescribing Guidelines
Read More
Quarterly Update for Partners For Kids Pediatric-Focused Unified Preferred Drug List (UPDL)
Read More
Quarterly Update for Partners For Kids Pediatric-Focused Unified Preferred Drug List (UPDL)
Read More
Updated Attention Deficit Hyperactivity Disorder (ADHD) Guidelines are Now Available – Central Region
Resources within the guideline include screening tools, treatment algorithms, and medication dosing recommendations.
Read More